<DOC>
	<DOCNO>NCT01291901</DOCNO>
	<brief_summary>The purpose study examine impact intradermal delivery NP2 pain score pain medication usage subject intractable pain due malignant disease . A second purpose confirm safety secondary efficacy measurement .</brief_summary>
	<brief_title>NP2 Enkephalin For Treatment Intractable Cancer Pain</brief_title>
	<detailed_description>Chronic severe pain remain significant unmet medical need patient progressive cancer . Existing treatment limited efficacy also suffer significant side effect . This multi-center , randomize , double blind , placebo-controlled clinical trial design evaluate impact intradermal injection NP2 subject intractable pain due malignant disease . NP2 gene transfer vector engineer express human preproenkephalin , gene naturally involved pain control . Delivery NP2 directly site pain cause cancer intend provide increase Enkephalin peptide , bind opioid receptor , may allow good pain control .</detailed_description>
	<mesh_term>Pain , Intractable</mesh_term>
	<mesh_term>Enkephalins</mesh_term>
	<criteria>Main Histologically confirm malignant disease . Intractable pain related malignancy . Females must postmenopausal practice birth control . Able provide appropriate write consent . Main Positive pregnancy test prior receive study treatment . Serious uncontrolled medical condition malignancy ( e.g . congestive heart failure , coagulopathy , uncontrolled diabetes ) . Evidence active Hepatitis B , Hepatitis C , HIV infection . Evidence viral , bacterial , fungal infection plan treatment area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>pain</keyword>
	<keyword>cancer</keyword>
	<keyword>malignancy</keyword>
	<keyword>intractable</keyword>
	<keyword>gene therapy</keyword>
	<keyword>enkephalin</keyword>
	<keyword>opioid</keyword>
</DOC>